NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Price, News & Analysis $20.15 -0.71 (-3.38%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Assembly Biosciences Stock (NASDAQ:ASMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Assembly Biosciences alerts:Sign Up Key Stats Today's Range$20.05▼$21.0050-Day Range$19.67▼$36.7252-Week Range$19.30▼$39.71Volume55,115 shsAverage Volume190,490 shsMarket Capitalization$410.34 millionP/E Ratio19.69Dividend YieldN/APrice Target$47.50Consensus RatingModerate Buy Company Overview Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral infections. The company’s research programs target chronic hepatitis B virus (HBV) infection and herpesvirus infections, including herpes simplex virus (HSV), with the goal of addressing diseases for which existing treatments may not provide adequate cures or long-term control. Assembly’s pipeline includes novel antiviral candidates designed to interfere with essential stages of viral replication. Its herpesvirus programs include investigational helicase-primase inhibitors such as ABI-5366, a long-acting candidate being developed for recurrent genital herpes, as well as additional discovery and development programs. The company has also advanced capsid assembly modulators and other antiviral approaches for HBV. Assembly has historically focused on developing first-in-class or differentiated antiviral medicines through internal research and strategic collaborations. The company previously advanced vebicorvir, an HBV capsid assembly modulator, and has worked with Gilead Sciences on HBV drug development. Its programs are evaluated through clinical and preclinical studies intended to support potential treatment options for patients worldwide.AI Generated. May Contain Errors. Read More Assembly Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreASMB MarketRank™: 2.951962809915 of 5 starsAssembly Biosciences scored higher than 59% of companies evaluated by MarketBeat, and ranked 357th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAssembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAssembly Biosciences has a consensus price target of $47.50, representing about 135.2% upside from its current price of $20.19.Amount of Analyst CoverageAssembly Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Assembly Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-97.81% Earnings GrowthEarnings for Assembly Biosciences are expected to decrease by -97.81% in the coming year, from $2.28 to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is 19.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is 19.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.61.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Assembly Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.83% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 11.07, which indicates bearish sentiment.Change versus previous monthShort interest in Assembly Biosciences has recently increased by 3.23%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.96 News SentimentAssembly Biosciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Assembly Biosciences this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.50% of the stock of Assembly Biosciences is held by insiders.Percentage Held by Institutions19.92% of the stock of Assembly Biosciences is held by institutions.Read more about Assembly Biosciences' insider trading history. Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASMB Stock News HeadlinesAssembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta VirusOctober 29 at 4:00 PM | globenewswire.comAssembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver MeetingOctober 6, 2026 | marketscreener.comMMissed SpaceX’s 1,000% winner? Then this is for you…In 2024, SpaceX began ordering from a tiny supplier called Filtronic. Its stock has since climbed more than 1,000 percent. Now Elon Musk is reportedly moving forward on a 119 billion dollar plan, and one overlooked American company has become critical to it. Larry Benedict, a former 900 million dollar hedge fund manager, breaks down the ticker and how investors are getting involved.October 30 at 1:00 AM | Brownstone Research (Ad)Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 ProgramOctober 6, 2026 | finance.yahoo.comAssembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026October 5, 2026 | globenewswire.comAssembly Biosciences (ASMB) Receives a Buy from Mizuho SecuritiesSeptember 12, 2026 | theglobeandmail.comAssembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceSeptember 10, 2026 | markets.businessinsider.comAssembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comSee More Headlines ASMB Stock Analysis - Frequently Asked Questions How have ASMB shares performed this year? Assembly Biosciences' stock was trading at $34.01 at the start of the year. Since then, ASMB shares have decreased by 40.6% and is now trading at $20.1920. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.52. The biopharmaceutical company earned $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative trailing twelve-month return on equity of 0.02% and a negative net margin of 0.06%. When did Assembly Biosciences' stock split? Shares of Assembly Biosciences reverse split on the morning of Monday, February 12th 2024.The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Assembly Biosciences IPO? Assembly Biosciences (ASMB) raised $19 million in an IPO on Thursday, December 16th 2010. The company issued 2,900,000 shares at a price of $6.00-$7.00 per share. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Bristol Myers Squibb (BMY), NIO (NIO), Pfizer (PFE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/13/2026Today10/30/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, ASMB's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASMB CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees73Year Founded2005Price Target and Rating Average Price Target for Assembly Biosciences$47.50 High Price Target$52.00 Low Price Target$43.00 Potential Upside/Downside+135.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$1.02 Trailing P/E Ratio19.78 Forward P/E Ratio8.84 P/E GrowthN/ANet Income-$6.12 million Net Margins-0.06% Pretax Margin-0.06% Return on Equity-0.02% Return on Assets-0.02% Debt Debt-to-Equity RatioN/A Current Ratio13.99 Quick Ratio13.99 Sales & Book Value Annual Sales$72.30 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book1.55Miscellaneous Outstanding Shares20,360,000Free Float19,648,000Market Cap$410.23 million OptionableOptionable Beta1.15 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ASMB) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
